The metabolic approach to improving prognosis in ischemic heart disease

Heart and Metabolism

Volumn , Issue 36, 2007, Pages 27-31

  Di Napoli, Pericle ^a,b  

^a Villa Pini d'Abruzzo Clinic   (Italy)

^b Dipartimento di Cardiologia   (Italy)

Author keywords

Heart failure; Ischemic heart disease; Prognosis; Trimetazidine

Indexed keywords

ACETYL COENZYME A ACYLTRANSFERASE; ADENOSINE TRIPHOSPHATE; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CARNITINE PALMITOYLTRANSFERASE; CREATINE PHOSPHATE; FATTY ACID; GLUCOSE; RANOLAZINE; TRIMETAZIDINE; TROPONIN T;

AGED; CARBOHYDRATE METABOLISM; CLINICAL ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIAGNOSTIC APPROACH ROUTE; DISEASE MARKER; ENERGY METABOLISM; ENERGY TRANSFER; FATTY ACID METABOLISM; GLUCOSE METABOLISM; HEART FAILURE; HEART MUSCLE METABOLISM; HEART MUSCLE OXYGEN CONSUMPTION; HEART VENTRICLE FUNCTION; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; METABOLIC REGULATION; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 36049020878     PISSN: 15660338     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Morrow A, Gersh J, Braunwald E. Chronic coronary heart disease. In: Zipes D, Libby P, Bonow R, Braunwald E, eds. Braunwald's Heart Disease - A Textbook of Cardiovascular Medicine. 7th edn. Philadelphia: Elsevier-Saunders; 2005. pp. 3-118.
2. Felker GM, Shaw LK,O'Connor CM. A standardized definition of ischemic cardiomyopathy for use in clinical research. J Am Coll Cardiol. 2002;39:210-208.
3. Fox K, Garcia MA, Ardissino D, et al., for the Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology; ESC Committee for Practice Guidelines (CPG). Guidelines on the management of stable angina pectoris: executive summary: the Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J. 2006;27:1341-1381.
4. Lee L, Horowitz J, Frenneaux M. Metabolic manipulation in ischemic heart disease, a novel approach to treatment. Eur Heart J. 2004;25:634-641.
5. Sharpe N. Cardiac remodelling in coronary artery disease. Am J Cardiol. 2004;93 (suppl):17B-20B.
6. Bleumink GS, Knetsch AM, Sturkenboom MC, et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure. Eur Heart J. 2004;25:1614-1619.
7. Jessup M, Brozena S. Heart failure. N Engl J Med. 2003;348:2007-2018.
8. Mann D. Mechanism and models in heart failure: a combinatorial approach. Circulation. 1999;100:999-1008.
9. Oliver MF. Glucose, insulin, potassium in acute myocardial infarction. Acta Cardiol. 1973;28:257-266.
10. Lewis CM, Brink AJ. Beta adrenergic blockade. Hemodynamics and myocardial energy metabolism in patients with ischemic heart disease. Am J Cardiol. 1968;21:846-859.
11. Armstrong PW, Chiong MA, Parker JO. Effects of propranolol on the hemodynamic, coronary sinus blood flow and myocardial metabolic response to atrial pacing. Am J Cardiol. 1977;40:83-89.
12. Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. 2000;86:580-588.
13. Lopaschuck GD, Stanley WC. Glucose metabolism in the ischemic heart. Circulation. 1997;95:313-315.
14. Bouvy ML, Heerdink ER, Leufkens HG, Hoes AW. Predicting mortality in patients with heart failure: a pragmatic approach. Heart. 2003;89:605-609.
15. Cowie MR, Wood DA, Coats AJ, et al. Survival of patients with a new diagnosis of heart failure: a population based study. Heart. 2000;83:505-510.
16. Scrutinio D, Lagioia R, Ricci A, Clemente M, Boni L, Rizzon P. Prediction of mortality in mild to moderately symptomatic patients with left ventricular dysfunction. The role of the New York Heart Association classification, cardiopulmonary exercise testing, two-dimensional echocardiography and Holter monitoring. Eur Heart J. 1994;15:1089-1095.
17. Koglin J, Pehlivanli S, Schwaiblmair M, Vogeser M, Cremer P, vonScheidt W. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol. 2001;38:1934-1941.
18. St John Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation. 2000;101:2981-2988.
19. Sato Y, Kita T, Takatsu Y, Kimura T. Biochemical markers of myocyte injury in heart failure. Heart. 2004;90:1110-1113.
20. Belardinelli R, Purcaro A. Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischemic cardiomyopathy. Eur Heart J. 2001;22:2164-2170.
21. Fragasso G, Perseghin G, De Cobelli F, et al. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J. 2006;27:942-948.
22. Neubauer S, Horn M, Cramer M, et al. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation. 1997;96:2190-2196.
23. Brottier L, Barat JL, Combe C, Boussens B, Bonnet J, Bricaud H. Therapeutic value of a cardioprotective agent in patients with severe ischemic cardiomyopathy. Eur Heart J. 1990;11:207-212.
24. Di Napoli P, Taccardi AA, Barsotti A. Long-term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischemic dilated cardiomyopathy. Heart. 2005;91:161-165.
25. Vitale C, Wajngaten M, Sposato B, et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J. 2004;25:1814-1821.
26. Fragasso G, Piatti PM, Monti L, et al. Short and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am Heart J. 2003;146:E18-E25.
27. Alonso-Martinez JL, Llorente-Diez B, Echegaray-Agara M, Olaz-Preciado F, Urbieta-Echezarreta M, González-Arencibia C. C-reactive protein as a predictor of improvement and readmission in heart failure. Eur J Heart Fail. 2002;4:331-336.
28. Williams FM, Tanda K, Kus M, Willians TJ. Trimetazidine inhibits neutrophil accumulation after myocardial ischemia and reperfusion in rabbits. J Cardiovasc Pharmacol. 1993;22:828-833.
29. Di Napoli P, Chierchia S, Taccardi AA, et al. Trimetazidine improves post-ischemic recovery by preserving endothelial nitric oxide synthase expression in isolated working rat hearts. Nitric Oxide. 2007;16:228-236.
30. Fragasso G. Inhibition of free fatty acids metabolism as a therapeutic target in patients with heart failure. Int J Clin Pract. 2007;61:603-610.
31. Fragasso G, Palloshi A, Puccetti P, et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol. 2006;48:992-998.
32. El-Kady T, El-Sabban K, Gabaly M, Sabry A, Abdel-Hady S. Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy: a 24-month study. Am J Cardiovasc Drugs. 2005;5:271-278.